$-0.31
(Market cap
$277,217 Mln
Revenue (TTM)
$60,439 Mln
P/E Ratio
27
P/B Ratio
5.9
Div. Yield
1.8 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$7,309 Mln
-
ROE
0.2 %
-
ROCE
13.7 %
-
Industry P/E
--
-
EV/EBITDA
15.2
-
Debt to Equity
0.5
-
Book Value
$--
-
EPS
$5.9
-
Face value
--
-
Shares outstanding
1,550,862,203
10 Years Aggregate
CFO
$54,607.00 Mln
EBITDA
$79,906.00 Mln
Net Profit
$26,599.00 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
AstraZeneca - ADR
| -- | -- | -- | -- | -- | -- | -- |
|
BSE Sensex
| -8.9 | 2.5 | 2.2 | -5.7 | 6.8 | 8.0 | 11.3 |
|
S&P 100
| 5.5 | -1.3 | 11.0 | 23.4 | 21.0 | 13.7 | 14.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
178.4 | 277,216.6 | 60,439.0 | 10,389.0 | 24.2 | 22.3 | 27 | 5.9 |
| 3.0 | 1,512.7 | 58,183.5 | -7,984.2 | 8.0 | -8.4 | -- | 0.3 | |
| 83.4 | 20,547.2 | 4,746.0 | 838.0 | 23.6 | 10.8 | 35.8 | 2.7 | |
| 90.4 | 22,286.4 | 4,746.0 | 607.0 | 21.9 | 8.1 | 38.8 | 2.9 | |
| 171.8 | 40,103.4 | 25,612.3 | 83.7 | 3.4 | -- | 107.7 | 136.7 | |
| 10.0 | 11,717.7 | 29,368.0 | -605.0 | -17.3 | -5.2 | 349 | 1.0 | |
| 137.3 | 21,217.7 | 4,965.5 | 201.5 | 4.5 | 7.6 | 106.4 | 7.9 | |
| 100.9 | 174,241.6 | 97,263.0 | 11,224.0 | 14.3 | 9.3 | 16.1 | 1.6 | |
| 26.2 | 67,642.6 | 37,210.0 | -1,736.0 | 3.1 | -5.1 | 93.3 | 2.1 |
Shareholding Pattern
View DetailsAbout AstraZeneca - ADR
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys,... Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Read more
-
CEO & Executive Director
Mr. Pascal Soriot D.V.M., M.B.A.
-
CEO & Executive Director
Mr. Pascal Soriot D.V.M., M.B.A.
-
Headquarters
Cambridge
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for AstraZeneca - ADR
What is the current share price of AstraZeneca PLC - ADR Today?
The share price of AstraZeneca PLC - ADR is $178.40 (NYSE) and $177.89 (NASDAQ) as of 17-Jun-2026 15:48 EDT. AstraZeneca PLC - ADR has given a return of --% in the last 1 years.
What is the current PB & PE ratio of AstraZeneca PLC - ADR?
The P/E ratio of AstraZeneca PLC - ADR is 26.96 times as on 12-Jun-2026.
The P/B ratio of AstraZeneca PLC - ADR is 5.86 times as on 12-Jun-2026, a 893 premium to its peers’ median range of 0.59 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
28.00
|
5.90
|
|
2024
|
14.56
|
2.51
|
|
2023
|
17.67
|
2.69
|
|
2022
|
32.17
|
2.86
|
|
2021
|
742.17
|
2.12
|
What is the 52 Week High and Low of AstraZeneca PLC - ADR?
The 52-week high and low of AstraZeneca PLC - ADR are Rs 190.72 and Rs 174.60 as of 18-Jun-2026.
What is the market cap of AstraZeneca PLC - ADR?
AstraZeneca PLC - ADR has a market capitalisation of $ 277,217 Mln as on 12-Jun-2026. As per SEBI classification, it is a Large Cap company.
Should I invest in AstraZeneca PLC - ADR?
Before investing in AstraZeneca PLC - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.